The Latest Breaking News from argenx

Argenx stock is rising Wednesday as the major indexes sell off. The autoimmune disease treatment stock is climbing in an early-stage base.

Argenx stock jumped Friday after the FDA cleared its autoimmune disease drug, Vyvgart Hytrulo, for at-home treatment.

Argenx stock surged Monday after the FDA approved its drug, Vyvgart Hytrulo, for patients with an autoimmune condition known as CIDP.

Immunovant stock slumped Thursday — reversing a day-earlier jump — after pivoting its focus to what one analyst called "a backup compound."

Biohaven stock tumbled Wednesday after the company's experimental protein-degrading drug lagged investor expectations.

Biotech stocks Argenx and Immunovant surged Thursday — and Tourmaline fell — on a rival's lackluster muscle disease drug study.

The biotechnology industry is booming thanks to growing demand for innovative healthcare solutions, favorable government initiatives, and several scientific breakthroughs. Thus, quality biotech stocks Genmab (GMAB), Halozyme Therapeutics (HALO), and Vertex Pharmaceuticals (VRTX) could be ideal buys for substantial profits. Read more….

Argenx stock crashed early Wednesday after its treatment for an autoimmune disease that causes skin blisters flopped in a Phase 3 study.

The Dow Jones pushed higher, but the Nasdaq slipped despite strong software earnings and a Fed shift toward rate cuts. Tesla Cybertruck deliveries began.